• 1. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

Research Brief on 5-(4-methylnaphthalen-1-yl)-1,2-oxazol-3-amine (CAS: 2229443-57-4): Recent Advances and Applications

The compound 5-(4-methylnaphthalen-1-yl)-1,2-oxazol-3-amine (CAS: 2229443-57-4) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. The brief is designed to provide researchers and industry professionals with a comprehensive overview of the current state of knowledge regarding this molecule.

Recent studies have highlighted the unique structural features of 5-(4-methylnaphthalen-1-yl)-1,2-oxazol-3-amine, which contribute to its interaction with various biological targets. The compound's oxazole core, coupled with the naphthalene moiety, has been shown to exhibit promising binding affinities for enzymes and receptors implicated in inflammatory and oncogenic pathways. This dual functionality makes it a versatile scaffold for further medicinal chemistry optimization.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers demonstrated the compound's efficacy as a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme associated with inflammation and pain. The study reported a significant reduction in inflammatory markers in animal models, with minimal gastrointestinal side effects—a common drawback of traditional COX-2 inhibitors. These findings suggest that 5-(4-methylnaphthalen-1-yl)-1,2-oxazol-3-amine could serve as a lead compound for developing safer anti-inflammatory drugs.

Another area of active research involves the compound's potential anticancer properties. Preliminary in vitro studies have shown that 5-(4-methylnaphthalen-1-yl)-1,2-oxazol-3-amine induces apoptosis in certain cancer cell lines, particularly those resistant to conventional chemotherapy. The mechanism appears to involve the disruption of mitochondrial membrane potential and activation of caspase pathways. While these results are promising, further in vivo studies are needed to validate the compound's efficacy and safety profile.

The synthesis of 5-(4-methylnaphthalen-1-yl)-1,2-oxazol-3-amine has also seen advancements, with recent publications describing more efficient and scalable routes. A 2024 paper in Organic Process Research & Development outlined a novel one-pot synthesis method that improves yield and reduces waste, addressing some of the challenges associated with large-scale production. This development is particularly relevant for pharmaceutical companies considering the compound for clinical development.

Despite these encouraging findings, several challenges remain. The compound's pharmacokinetic properties, including its bioavailability and metabolic stability, require further optimization. Additionally, more comprehensive toxicological studies are necessary to fully assess its safety profile. These gaps present opportunities for future research and collaboration between academic and industrial partners.

In conclusion, 5-(4-methylnaphthalen-1-yl)-1,2-oxazol-3-amine represents a promising candidate for multiple therapeutic applications. Its unique chemical structure and demonstrated biological activities make it worthy of continued investigation. As research progresses, this compound may pave the way for novel treatments in inflammation and oncology, addressing unmet medical needs in these areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)